Acorn Capital Advisors, LLC reported 22 holdings worth US$364M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Acorn Capital Advisors, LLC reported 22 holdings worth US$364M as of Sep 30, 2026. Largest: CG Oncology, Inc., Puma Biotechnology Inc and Candel Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 22
- Value as reported
- US$364M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| CG Oncology, Inc. | 1.13M | US$80.2M | 22.0% |
| Puma Biotechnology Inc | 4.13M | US$41M | 11.3% |
| Candel Therapeutics, Inc. | 3.5M | US$36.5M | 10.0% |
| Trevi Therapeutics, Inc. | 2.14M | US$30.7M | 8.4% |
| Cybin, Inc. | 1.54M | US$18.9M | 5.2% |
| Jade Biosciences, Inc. | 987K | US$13.9M | 3.8% |
| Bicara Therapeutics Inc. | 668K | US$12.4M | 3.4% |
| Verastem, Inc. | 1.47M | US$11.8M | 3.2% |
| OnKure Therapeutics, Inc. | 2.84M | US$7.75M | 2.1% |
| AN2 Therapeutics, Inc. | 1.3M | US$6.92M | 1.9% |
| Aura Biosciences, Inc. | 1.03M | US$6.44M | 1.8% |
| Protara Therapeutics, Inc. | 1.75M | US$5.34M | 1.5% |
| Annexon, Inc. | 1.14M | US$4.81M | 1.3% |
| LeonaBio, Inc. | 1.14M | US$4.09M | 1.1% |
| Whitehawk Therapeutics, Inc. | 932K | US$3.5M | 0.96% |
| Q32 Bio Inc. | 216K | US$1.79M | 0.49% |
| Karyopharm Therapeutics Inc. | 1.22M | US$1.49M | 0.41% |
| Jasper Therapeutics, Inc. | 1.44M | US$834K | 0.23% |
| VYNE Therapeutics Inc. | 32,005 | US$721K | 0.20% |
Source
Download original · View original at SEC